RSRooban Sivakumar

Rooban Sivakumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rooban Sivakumar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Arul Senghor Kadalangudi Aravaanan

    Department of Biochemistry, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, SRM Nagar

    6 shared publications
  • V. M. Vinodhini

    Department of Biochemistry, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, SRM Nagar

    4 shared publications
  • Janardhanan Kumar

    Department of General Medicine, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology

    3 shared publications
  • K. A. Arul Senghor

    Department of Biochemistry, Faculty of Medicine and Health Sciences, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, Kanchipuram, Chennai, 603203, Tamil Nadu, India

    3 shared publications
  • Arul Senghor Kadalangudi Aravaanan

    Department of Biochemistry, SRM Medical College Hospital and Research Centre, SRM Institute of Science andTechnology, SRM Nagar, Kattankulathur – 603203, Kanchipuram, Chennai, Tamil Nadu, India

    2 shared publications
  • J.S. Kumar

    2 shared publications

Latest Publications

  • Open Access

    ENHO and EDN1 variants link adropin–endothelin-1 imbalance with early vascular aging in adults with and without type 2 diabetes

    by Rooban Sivakumar, K. A. Arul Senghor, V. M. Vinodhini, Janardhanan Kumar

    Background: Early vascular aging (EVA) is common in type 2 diabetes, yet its inherited determinants remain undefined. This study examined the associations of ENHO and EDN1 genetic variation with circulating adropin, endothelin-1, their relative imbalance, and early vascular aging in adults with and without T2DM. Methods: This study included 300 adults aged 25–55 years, comprising 150 participants with T2DM and 150 age- and sex-matched controls. Participants were further classified as having Early vascular aging (EVA) (n=116) or Normal vascular aging (NVA) (n=184) using age-referenced estimated pulse wave velocity. ENHO rs2281997 and rs72735260, and EDN1 rs5370 and rs2070699 were genotyped by HRM analysis with Sanger confirmation. Gene-specific and total genetic risk scores (GRS) were tested against adropin, endothelin-1, the adropin–endothelin-1 imbalance index (AEI), EVA, and continuous ePWV. Results: In the overall cohort, all four variants were associated with EVA in the risk direction. rs5370 and rs72735260 remained significant after FDR correction. Each additional risk allele in the Total GRS increased the adjusted odds of EVA by 69% (OR 1.691, 95% CI 1.381–2.094), with a graded increase across genetic burden categories. Higher ENHO-GRS was associated with lower adropin, higher EDN1-GRS with higher endothelin-1, and higher Total GRS with greater AEI, which statistically mediated 51.8% of the GRS–EVA association. Within the study cohort, AEI discriminated EVA better than GRS (AUC 0.776 vs 0.661). Conclusions: Combined ENHO – EDN1 genetic burden is associated with an adverse adropin–endothelin-1 balance and early vascular aging. Independent replication is required before clinical application.

  • Open Access

    Genetic polymorphisms and hypertension in Indian populations: a systematic review and integrative bioinformatics approach

    by Rooban Sivakumar, Prasath N, Lakshmi Vijukumar, Arul Senghor K. A, Renuka P, Vinodhini V. M

    Hypertension continues to be a major public health issue in India, with increasing incidence associated with both lifestyle factors and genetic susceptibil

  • Open Access

    Development of a biomarker-enhanced arterial age model for young-to-middle-aged adults with type 2 diabetes

    by Rooban Sivakumar, K. A. Arul Senghor, V. M. Vinodhini, J. S. Kumar

    Direct vascular aging assessment is not always feasible in routine diabetes care. We aimed to derive a control-based arterial age reference using estimated pulse wave velocity, develop a biomarker-enhanced model for predicting arterial age gap, and evaluate its ability to identify accelerated arterial aging in young-to-middle-aged adults with type 2 diabetes mellitus. This study included 300 participants (150 T2DM, 150 age- and sex-matched controls). Arterial age was derived from a control-group ePWV-age regression. Age gap was defined as estimated arterial age minus chronological age. Candidate predictors were evaluated using multivariable linear regression, and the final model was internally validated by 10-fold cross-validation. Compared with controls, participants with T2DM had higher ePWV, older estimated arterial age, larger age gap, lower adropin, and higher oxLDL (all p < 0.001). Accelerated arterial aging was more frequent in T2DM than controls (76.0% vs. 20.0%). The final model integrating HbA1c, adropin, and oxLDL explained 42% of the variance in age gap (adjusted R²=0.418), showed good discrimination for accelerated arterial aging (AUC 0.889; 95% CI 0.828-0.910), and retained acceptable internal calibration (slope 0.943). A biomarker-enhanced arterial age model integrating HbA1c, adropin, and oxLDL provided an interpretable framework for identifying accelerated arterial aging in young-to-middle-aged adults with T2DM. Although promising for translational implementation, external validation and direct pulse wave velocity benchmarking are required before clinical application. The model also enabled a three-level arterial aging classification and web-based implementation for research use, supporting its potential as a practical risk-communication tool prototype.


  • Open Access

    Adropin and Endothelin-1 as Complementary Signals Associated with Early Vascular Aging in Middle-Aged Type 2 Diabetes

    by Rooban Sivakumar, Arul Senghor Kadalangudi Aravaanan, Vinodhini Vellore Mohanakrishnan, Janardhanan Kumar

    Background: Early vascular aging (EVA) is a common complication of type 2 diabetes mellitus. Early identification is crucial in middle-aged individuals with T2DM, as vascular stiffness can occur gradually for years before cardiovascular disease. However, EVA is rarely considered in routine care. Adropin is a vasoprotective peptide that may counter-regulate endothelin-1 (ET-1). Therefore, this study aims to examine the association between circulating adropin, ET-1, oxLDL, MMP-2, VEGFA, and EVA. Methods: This observational study included 300 adults aged 25–55 years (150 T2DM; 150 age/sex-matched controls). ePWV was calculated from age and mean blood pressure. EVA was classified using a residual-based, age-specific ePWV threshold derived from controls. Associations were tested using correlation and logistic regression. ROC and decision curve analyses were performed to evaluate diagnostic performance and clinical utility. Results: EVA prevalence was 38.6% overall, occurring in 7.3% of controls and increasing across T2DM with good and poor glycemic control (56.1% and 80.95%, respectively, p < 0.001). Compared with normal vascular aging, EVA showed lower adropin and higher ET-1, oxLDL and MMP-2, with lower VEGFA (all p < 0.05). In fully adjusted models, adropin (OR 0.991 per pg/mL; p < 0.001) and ET-1 (OR 1.017 per pg/mL, p = 0.005) remained independently associated with EVA. A combined adropin + ET-1 predictor improved discrimination (AUC 0.901, 95% CI 0.868–0.934), at a predicted-probability cutoff of 0.607, 78.7% sensitivity and 87.0% specificity. Conclusions: In middle-aged T2DM, EVA was associated with lower adropin and higher ET-1 in T2DM. These findings support an association between these biomarkers and the EVA phenotype.


  • Open Access

    In silico prioritisation of EDN1 missense variants identifies mature endothelin-1 substitutions with predicted receptor-binding effects

    by Rooban Sivakumar, K. A. Arul Senghor, V. M. Vinodhini, K. M. Ramkumar

    Endothelin-1 (ET-1) plays a major role in endothelial function and early vascular ageing (EVA). Although regulatory EDN1 variations have been investigated,


  • Open Access

    Mitochondrial-Derived Peptides as Therapeutics and Biomarkers for Combating Vascular Aging and Associated Cardiovascular Diseases

    by Rooban Sivakumar, Arul Senghor Kadalangudi Aravaanan, Vinodhini Vellore Mohanakrishnan, Janardhanan Kumar

    Vascular aging profoundly affects the onset of cardiovascular diseases in the elderly, mostly as a result of mitochondrial dysfunction. This review examines the protective roles of mitochondrial- derived peptides such as humanin, MOTS-c, and small humanin-like peptides in mitigating vascular aging. These peptides, encoded by mitochondrial DNA, are crucial for regulating apoptosis, inflammation, and oxidative stress, which have a major role in vascular health. MDPs have significant prospects as therapeutic and biomarker possibilities for the early diagnosis and intervention of vascular aging. MDPs influence the functions of endothelial and vascular smooth muscle cells by modulating critical signaling pathways, including AMPK, mTOR, and sirtuins. These pathways are essential for facilitating cellular metabolism, enhancing stress resilience, and prolonging longevity. Moreover, MDPs are essential in mitochondrial bioenergetics and dynamics, vital for mitigating endothelial dysfunction and enhancing vascular resilience. Furthermore, MDPs contribute to immunological modulation and the regulation of inflammatory responses, underscoring their potential therapeutic applications in the treatment of age-related vascular disorders. This review analyzes the various functions of MDPs in vascular health and their therapeutic importance, advocating for more studies to optimize their clinical benefits. By understanding the comprehensive roles and mechanisms of these multifunctional peptides, we can better appreciate their capacity to prevent and treat vascular aging and associated cardiovascular disorders. Future research should aim to further elucidate their therapeutic effects and optimize their clinical applications.


  • Open Access

    From Environment to Endothelium: The Role of Microplastics in Vascular Aging

    by Rooban Sivakumar, Arul Senghor Kadalangudi Aravaanan, Vinodhini Vellore Mohanakrishnan, Janardhanan Kumar

    Microplastics, synthetic polymer particles measuring less than 5 mm, have become a widespread environmental pollutant, raising concerns over their possible effects on human health. Growing evidence links MPs to vascular aging and cardiovascular disease beyond their ecological toxicity. Upon inhalation, ingestion, or skin contact, microplastics can traverse biological barriers, circulate systemically, and accumulate in vascular tissues. Experimental investigations indicate that MPs, especially polystyrene and polyethylene in nano- and micro-sized forms, induce oxidative stress, mitochondrial dysfunction, and chronic inflammation. These disruptions activate redox-sensitive signaling pathways, such as NF-κB and NLRP3 inflammasome, causing endothelial dysfunction, vascular smooth muscle modulation, and foam cell production, indicating early vascular aging. Animal models and in vitro studies have consistently shown endothelial activation, increased cytokine production, and changes in vascular tone after exposure to MPs. Initial human research has detected microplastics in blood, thrombi, and atherosclerotic plaques, which correlate with negative cardiovascular outcomes and systemic inflammation. Notably, recent research suggests that the gut microbiota and antioxidant systems may play a role in adaptive reactions, although these processes are still not fully understood. MP-induced vascular toxicity is covered in this interdisciplinary review, highlighting molecular pathways, experimental data, and translational gaps.


  • Metformin: An Old Drug with New Tricks—Promising Role in Vascular Aging and Cardioprotection

    by Rooban Sivakumar, K. A. Arul Senghor, V. M. Vinodhini, Janardhanan S. Kumar

    Metformin, traditionally promoted for its efficacy in diabetes, is increasingly appreciated for its geroprotective potential in the development of vascular aging, a key contributor to cardiovascular morbidity. This review aims at understanding the spectrum of mechanisms that govern the amelioration of degenerative processes associated with vascular aging by metformin. Central to this therapeutic promise is the activation of AMPK, which reduces metabolic dysregulation and hence slows vascular senescence. Oxidative stress has been identified as an important mechanism thought to be enhanced by metformin in the preservation of endothelial function and attenuation of arterial stiffening. Besides, metformin has lipid-lowering and antiinflammatory activity, which is critical for reducing arterial rigidity and the development of atherosclerotic plaque. In recent times, both clinical and preclinical studies revealed empirical data that confirmed the effectiveness of metformin in the improvement of endothelial function and the decreasing of arterial stiffness as a part of a reduction in the rates of cardiovascular events. The therapeutic action of the drug goes beyond glycemic control, rendering it a geroprotector potentially suitable for broader application in age-related vascular decline. In light of these findings, the clinical acceptance of metformin as an intervention in vascular aging should be possible and promising. Carefully monitored follow-up studies are needed to optimize dosing, delineate the broad biological effects, and verify long-term benefits, which will underpin metformin’s role in the paradigm against age-associated vascular diseases


  • Open Access

    The Emerging Role of Adropin in Neurological Health: A Systematic Review

    by Rooban Sivakumar, Arul Senghor Kadalangudi Aravaanan, Vinodhini Vellore Mohanakrishnan, Janardhanan Kumar

    Background: Adropin, a peptide hormone has role in various various physiological processes, including metabolic regulation and cardiovascular health. This systematic review aimed to synthesize findings from observational studies on the involvement of adropin in neurological disorders and cognitive performance. Methods: An extensive literature search was conducted across PubMed, Scopus, Web of Science, Embase, CORE, and Google Scholar using terms such as "adropin," "Neurological Disorders," "cognitive function," "Alzheimer's disease," "Parkinson's disease," "cognition," and "brain function." Studies published from 2020 to 2024 were selected and reviewed. The search and selection process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Out of 127 screened articles, 5 met the inclusion criteria for this review. Results: The combined research findings suggest a consistent link between decreased adropin levels and a range of neurological disorders and cognitive impairments. In particular, reduced adropin levels were seen in individuals with dementia, cognitive impairment, bipolar disorder, Parkinson's disease, and multiple sclerosis. These findings highlight adropin's potential role in modulating neurological health and cognitive function. Conclusion: This systematic review underscores the importance of adropin in neurological health and its potential as a therapeutic agent. Based on the observed connections, adropin might serve as a new focus for treating neurological disorders, prompting the need for more research and trials.